GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Troels K. BergmannSchool of Pharmacy, University of Queensland, Brisbane, Australia;Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, DenmarkCorrespondence[email protected]

Werner VachClinical Epidemiology, Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany

Søren FeddersenDepartment of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark

Lise EckhoffDepartment of Oncology, Odense University Hospital, Odense, Denmark

Henrik GréenClinical Pharmacology, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden;Science for Life Laboratory, School of Biotechnology, Division of Gene Technology, Royal Institute of Technology, Solna, Sweden

Jørn HerrstedtDepartment of Oncology, Odense University Hospital, Odense, Denmark

Kim BrosenClinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark

show all

GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date